MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
Glavni autori: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Conference item |
Jezik: | English |
Izdano: |
Elsevier
2022
|